CONTEXT: Candidiasis is a mycosis caused by Candida species, which is of clinical importance due to the increase in resistant yeasts. Candida infection has been a serious health problem due to the inappropriate use of antibiotics. Therefore, it is necessary to study molecules with an antifungal action. Citral is a monoterpene with known pharmacological properties, including antimicrobial action. OBJECTIVE: The aim of this work was to determine the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of citral and the probable mode of action. MATERIALS AND METHODS: The MIC of citral was determined by the broth microdilution method using Sabouraud dextrose medium. Additionally, the interference of citral in cell wall (sorbitol assay) and the binding of citral to ergosterol and cholesterol were studied, carried out by broth microdilution method. RESULTS: The MIC and MFC of citral were 512 and 1024 µg/mL, respectively. The MIC of amphotericin B was 1 µg/mL. The mechanism of action did not involve either the cell wall or ergosterol. However, the presence of cholesterol increased the MIC of citral to 1024 µg/mL, indicating there is some interaction between citral and cholesterol. Amphotericin B was used as the positive control, and it showed a high MIC in the presence of ergosterol (32 µg/mL), while in the presence of cholesterol MIC increased to 4 µg/mL. CONCLUSION: Citral inhibits the growth of C. albicans. The probable mechanism of action did not involve the cell wall or ergosterol. Citral is able to interact with cholesterol. More studies are necessary to describe their effects completely.
CONTEXT: Candidiasis is a mycosis caused by Candida species, which is of clinical importance due to the increase in resistant yeasts. Candida infection has been a serious health problem due to the inappropriate use of antibiotics. Therefore, it is necessary to study molecules with an antifungal action. Citral is a monoterpene with known pharmacological properties, including antimicrobial action. OBJECTIVE: The aim of this work was to determine the minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) of citral and the probable mode of action. MATERIALS AND METHODS: The MIC of citral was determined by the broth microdilution method using Sabouraud dextrose medium. Additionally, the interference of citral in cell wall (sorbitol assay) and the binding of citral to ergosterol and cholesterol were studied, carried out by broth microdilution method. RESULTS: The MIC and MFC of citral were 512 and 1024 µg/mL, respectively. The MIC of amphotericin B was 1 µg/mL. The mechanism of action did not involve either the cell wall or ergosterol. However, the presence of cholesterol increased the MIC of citral to 1024 µg/mL, indicating there is some interaction between citral and cholesterol. Amphotericin B was used as the positive control, and it showed a high MIC in the presence of ergosterol (32 µg/mL), while in the presence of cholesterol MIC increased to 4 µg/mL. CONCLUSION:Citral inhibits the growth of C. albicans. The probable mechanism of action did not involve the cell wall or ergosterol. Citral is able to interact with cholesterol. More studies are necessary to describe their effects completely.
Authors: Fernando J Scariot; Mariliza S Pansera; Ana Paula L Delamare; Sergio Echeverrigaray Journal: World J Microbiol Biotechnol Date: 2021-02-06 Impact factor: 3.312
Authors: Anna Biernasiuk; Anna Berecka-Rycerz; Anna Gumieniczek; Maria Malm; Krzysztof Z Łączkowski; Jolanta Szymańska; Anna Malm Journal: Appl Microbiol Biotechnol Date: 2021-08-19 Impact factor: 4.813
Authors: Maria Clerya Alvino Leite; André Parente de Brito Bezerra; Janiere Pereira de Sousa; Felipe Queiroga Sarmento Guerra; Edeltrudes de Oliveira Lima Journal: Evid Based Complement Alternat Med Date: 2014-08-28 Impact factor: 2.629
Authors: Julliana Cariry Palhano Freire; José Klidenberg de Oliveira Júnior; Daniele de Figueredo Silva; Janiere Pereira de Sousa; Felipe Queiroga Sarmento Guerra; Edeltrudes de Oliveira Lima Journal: Evid Based Complement Alternat Med Date: 2017-09-26 Impact factor: 2.629
Authors: Shailee V Tiwari; Julio A Seijas; Maria Pilar Vazquez-Tato; Aniket P Sarkate; Kshipra S Karnik; Anna Pratima G Nikalje Journal: Molecules Date: 2018-02-16 Impact factor: 4.411
Authors: Shailee V Tiwari; Julio A Seijas; Maria Pilar Vazquez-Tato; Aniket P Sarkate; Kshipra S Karnik; Anna Pratima G Nikalje Journal: Molecules Date: 2017-07-13 Impact factor: 4.411